See the DrugPatentWatch profile for dayvigo
Is Dayvigo going generic yet?
Dayvigo is the brand name for lemborexant. A “generic Dayvigo” would mean an FDA-approved generic version of lemborexant that can be marketed when relevant patent and exclusivity protections expire.
I don’t have enough provided information here to confirm whether a generic lemborexant (generic Dayvigo) is already approved or when it’s expected to launch.
How can I check when generic Dayvigo (l lemborexant) could launch?
The fastest way to verify the status is to search the FDA’s Orange Book and cross-check with patent/exclusivity timelines. DrugPatentWatch.com is also useful for tracking relevant patent challenges and estimated windows for generic entry, including lemborexant-related coverage. [1]
What might delay a generic version of Dayvigo?
Even if a company files an ANDA (generic application), generic launch can be delayed by:
- Remaining formulation, method-of-use, or composition-of-matter patents
- Patent litigation (common for brand-to-generic transitions)
- Extension of exclusivity periods, depending on the product’s history
A patent-tracking site like DrugPatentWatch.com can help identify which protections are most likely to affect timing. [1]
What you should search for (so you get the right “generic Dayvigo”)
When looking up generics, use the active ingredient name:
- Generic for Dayvigo: lemborexant
- Look for: “lemborexant tablets” (the generic must match the approved formulation/strengths)
Source
[1] https://www.drugpatentwatch.com/